曲伏前列腺素滴眼液降眼压效果的临床观察

A clinical observation on travoprost eye drops (Travatan) reducing IOP

目的评价曲伏前列腺素滴眼液(苏为坦)降眼压治疗的有效性和安全性。方法20例(38只眼)原发性青光眼/高眼压症患者单用或联合点用曲伏前列腺素滴眼液,每晚1次,随访12周,观察眼压、视野及不良反应。结果曲伏前列腺素滴眼液能显著降低眼压(P<0.01),12周后降眼压幅度范围6～14mmHg,视野平均缺损与治疗前比较无显著性差异(P>0.01)。不良反应主要为轻至中度的结膜充血。结论曲伏前列腺素滴眼液能显著降低原发性青光眼/高眼压症等患者的眼压,而且安全、有较好的耐受性。

Objective To evaluate the efficacy and safety of travoprost reducing lOP. Methods 38 eyes of 20 primary glaucoma / ocular hypertension patients were dosed with travoprost as a single therapy / as adjunctive therapy once daily. The observed signs included lOP, visual field and complications. The follow-up duration was 12 weeks. Results Travoprost reduced lOP significantly （ P 〈0.01 ）. After 12 weeks, lOP reductions ranged from 6 to 14 mmHg ,and Mean defect in visual field didnt change significantly compared with that of pre-treatment. The most complications was mild to moderate ocular hyperemia. Conclusion Travoprost reduced lOP significantly in primary glaucoma / ocular hypertension patients, and was safe and well tolerated.